Joseph Baroldi sold $531k of IONS
EVP, Chief Business Officer at IONIS PHARMACEUTICALS INC. 6,659 shares at an average of $79.74, traded Mar 3, 2026, filed Mar 5, 2026.
Score components
- +15RoleOfficer
- +18Trade size$531k at market
- +5Share of holdings soldSold 15% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-26-000133, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -4,096 | $79.36 | $325k | 41,317 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Common Stockindirect: by Spouse10b5-1 | +820 | $56.78 | $47k | 5,592 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Common Stockindirect: by Spouse10b5-1 | +879 | $32.60 | $29k | 6,471 | Mar 5, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stockindirect: by Spouse10b5-1 | -2,088 | $80.41 | $168k | 4,383 | Mar 5, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stockindirect: by Spouse10b5-1 | -36 | $81.01 | $2,916 | 4,347 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Common Stockindirect: by Spouse10b5-1 | +238 | $56.78 | $14k | 4,585 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stockindirect: by Spouse10b5-1 | -238 | $80.00 | $19k | 4,347 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Common Stockindirect: by Spouse10b5-1 | +201 | $32.60 | $6,553 | 4,548 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stockindirect: by Spouse10b5-1 | -201 | $80.00 | $16k | 4,347 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivativeindirect: by Spouse10b5-1 | -879 | $0.00 | $0 | 1,970 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivativeindirect: by Spouse10b5-1 | -201 | $0.00 | $0 | 1,769 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivativeindirect: by Spouse10b5-1 | -820 | $0.00 | $0 | 4,104 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivativeindirect: by Spouse10b5-1 | -238 | $0.00 | $0 | 3,866 | Mar 5, 2026 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $6.7M 85,089 shares | -51% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $7.1M 85,089 shares | -85% | |
| 48Moderate | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $488k 5,885 shares | -6% | |
| 52Moderate | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $439k 5,296 shares | -10% | |
| 48Moderate | IONIS PHARMACEUTICALS INC | Brian Birchler EVP, Corp and Development Ops | $513k 6,179 shares | -9% | |
| 35Weak | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $675k 8,977 shares | -9% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $610k 8,056 shares | -17% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Brian Birchler EVP, Corp and Development Ops | $637k 8,480 shares | -12% | |
| 45Moderate | IONIS PHARMACEUTICALS INC | Joseph H Wender director | $2.3M 28,000 shares | -44% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Shannon L. Devers EVP, Chief Human Resources Ofc | $1.4M 16,777 shares | -49% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.